Benzinga · Aug 19, 2026
JP Morgan Downgrades Mereo BioPharma Group to Underweight
JP Morgan analyst Priyanka Grover downgrades Mereo BioPharma Group (NASDAQ:MREO) from Neutral to Underweight.
MR
NASDAQ · MREO
Mereo BioPharma Group plc
Healthcare · Biotechnology
$0.24
Up+$0.00 (+0.87%)
Updated Sep 10, 2026, 9:12 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 360.84M
- P/E ratio
- -7.29
- Dividend yield
- 0.00%
- 52-week range
- $0.22 – $0.42
- Volume
- 2.95M
- Avg. volume
- 1.61M
Price performance
MREO price history
1M range · 20 trading sessions · Daily adjusted prices
MREO closed at $0.24 after 20 trading sessions, down 19.94% for the selected period.
- Last close
- $0.24
- Period change
- -19.94%
- Period low
- $0.24
- Period high
- $0.32
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $0.2559 | $0.2559 | $0.2385 | $0.2425 | 2.95M |
| Sep 8, 2026 | $0.25 | $0.2586 | $0.2451 | $0.2546 | 803.79K |
| Sep 4, 2026 | $0.272 | $0.272 | $0.2483 | $0.25 | 1.34M |
| Sep 3, 2026 | $0.264 | $0.2799 | $0.2626 | $0.2722 | 876.92K |
| Sep 2, 2026 | $0.27 | $0.2837 | $0.2626 | $0.2672 | 809.25K |
| Sep 1, 2026 | $0.27 | $0.2878 | $0.27 | $0.2767 | 1.56M |
| Aug 31, 2026 | $0.2525 | $0.288 | $0.2525 | $0.2668 | 1.31M |
| Aug 28, 2026 | $0.2657 | $0.2736 | $0.2519 | $0.2525 | 1.56M |
| Aug 27, 2026 | $0.2881 | $0.2881 | $0.2674 | $0.272 | 1.42M |
| Aug 26, 2026 | $0.2885 | $0.289 | $0.2761 | $0.278 | 1.02M |
| Aug 25, 2026 | $0.288 | $0.2926 | $0.281 | $0.2816 | 1.15M |
| Aug 24, 2026 | $0.29 | $0.294 | $0.2848 | $0.2895 | 799.39K |
| Aug 21, 2026 | $0.303 | $0.3058 | $0.2903 | $0.2904 | 714.7K |
| Aug 20, 2026 | $0.3078 | $0.3079 | $0.2926 | $0.2933 | 754.66K |
| Aug 19, 2026 | $0.286 | $0.3141 | $0.28 | $0.3115 | 1.21M |
| Aug 18, 2026 | $0.3067 | $0.315 | $0.2953 | $0.313 | 981.11K |
| Aug 17, 2026 | $0.3205 | $0.3214 | $0.2985 | $0.3077 | 1.45M |
| Aug 14, 2026 | $0.3001 | $0.3265 | $0.2956 | $0.3189 | 1.85M |
| Aug 13, 2026 | $0.3035 | $0.31 | $0.29 | $0.3077 | 2.29M |
| Aug 12, 2026 | $0.2903 | $0.303 | $0.281 | $0.3029 | 8.48M |
Latest MREO news
The latest Smart Investors Daily articles mentioning MREO.
Stock researchCompany · Overview
MREO research
Overview
Company profile and research snapshot.
Company profile
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | JP Morgan | Underweight | — |
| Aug 11, 2026 | Needham | Buy | — |
| Aug 11, 2026 | BTIG | Buy | — |
| May 12, 2026 | BTIG | Buy | — |
| Mar 23, 2026 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Mereo BioPharma Group Q2 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
Yahoo · May 13, 2026
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
European equities traded in the US as American depositary receipts were little changed late Wednesda
Yahoo · May 12, 2026
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading
European equities traded in the US as American depositary receipts were down significantly late Tues
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
